NASDAQ:CING Cingulate (CING) Stock Price, News & Analysis $5.19 +0.09 (+1.76%) Closing price 04:00 PM EasternExtended Trading$5.20 +0.01 (+0.29%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Cingulate Stock (NASDAQ:CING) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cingulate alerts:Sign Up Key Stats Today's Range$5.05▼$5.2850-Day Range$4.43▼$5.8952-Week Range$3.16▼$11.89Volume76,399 shsAverage Volume425,620 shsMarket Capitalization$75.46 millionP/E RatioN/ADividend YieldN/APrice Target$27.00Consensus RatingModerate Buy Company Overview Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas. Read More Cingulate Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreCING MarketRank™: Cingulate scored higher than 41% of companies evaluated by MarketBeat, and ranked 573rd out of 906 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingCingulate has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCingulate has a consensus price target of $27.00, representing about 420.2% upside from its current price of $5.19.Amount of Analyst CoverageCingulate has only been the subject of 2 research reports in the past 90 days.Read more about Cingulate's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cingulate are expected to grow in the coming year, from ($2.31) to ($1.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cingulate is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cingulate is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCingulate has a P/B Ratio of 16.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cingulate's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.74% of the float of Cingulate has been sold short.Short Interest Ratio / Days to CoverCingulate has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Cingulate has recently decreased by 23.35%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCingulate does not currently pay a dividend.Dividend GrowthCingulate does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 1 people have searched for CING on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Cingulate to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cingulate insiders have not sold or bought any company stock.Percentage Held by Insiders5.30% of the stock of Cingulate is held by insiders.Percentage Held by Institutions41.31% of the stock of Cingulate is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cingulate's insider trading history. Receive CING Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CING Stock News HeadlinesPsychedelic drug calms hyperactive brain cells linked to chronic painAugust 16, 2026 | msn.comCingulate Reports $5.9 Million Second-Quarter Loss, $28.4 Million CashAugust 13, 2026 | quiverquant.comQStocks Keep Climbing. Here's The Problem (and possible solution).Record highs and AI-fueled optimism have investors feeling confident - but every major bull market in history ended the same way, from the dot-com crash to 2008 to 2020. Preserve Gold, trusted by 800+ five-star reviewers, offers a free 2026 Gold and Silver Kit showing how to move part of an eligible 401(k) or IRA into physical metals tax and penalty free, plus up to $20,000 in cashback on qualified purchases.September 8 at 1:00 AM | Preserve Gold (Ad)Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial ReadinessAugust 13, 2026 | globenewswire.comCingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic ProfileAugust 11, 2026 | markets.businessinsider.comCingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent PsychopharmacologyJuly 30, 2026 | globenewswire.comCingulate enhances equity plan and updates board leadershipJuly 15, 2026 | tipranks.comCingulate Inc. (NASDAQ: CING) Added to Russell 3000E®July 2, 2026 | globenewswire.comSee More Headlines CING Stock Analysis - Frequently Asked Questions How have CING shares performed this year? Cingulate's stock was trading at $4.34 at the beginning of 2026. Since then, CING shares have increased by 19.6% and is now trading at $5.19. How were Cingulate's earnings last quarter? Cingulate Inc. (NASDAQ:CING) released its quarterly earnings results on Thursday, August, 13th. The company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.63) by $0.18. When did Cingulate's stock split? Shares of Cingulate reverse split before market open on Thursday, November 30th 2023.The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Cingulate IPO? Cingulate (CING) raised $29 million in an initial public offering (IPO) on Wednesday, December 8th 2021. The company issued 4,166,666 shares at $6.00-$8.00 per share. Who are Cingulate's major shareholders? Cingulate's top institutional investors include BlackRock Inc. (0.39%). Insiders that own company stock include Peter J Werth, Thomas Jeffrey Hargroves, Shane J Schaffer, Jennifer L Callahan, Matthew Brams and Laurie Myers. View institutional ownership trends. How do I buy shares of Cingulate? Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cingulate own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cingulate investors own include NVIDIA (NVDA), Windtree Therapeutics (WINT), AMC Entertainment (AMC), Sonnet BioTherapeutics (SONN), ARMOUR Residential REIT (ARR), BioCardia (BCDA) and Company Calendar Last Earnings8/13/2026Today9/08/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CING's financial health is in the Yellow zone, according to TradeSmith. CING has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CING CIK1862150 Webwww.cingulate.com Phone913-942-2300FaxN/AEmployees20Year Founded2012Price Target and Rating Average Price Target for Cingulate$27.00 High Price Target$52.00 Low Price Target$9.00 Potential Upside/Downside+418.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($3.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$22.45 million Net MarginsN/A Pretax MarginN/A Return on Equity-238.40% Return on Assets-128.67% Debt Debt-to-Equity RatioN/A Current Ratio3.50 Quick Ratio3.50 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book16.81Miscellaneous Outstanding Shares14,540,000Free Float13,771,000Market Cap$75.78 million OptionableNot Optionable Beta-0.88 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CING) was last updated on 9/8/2026 by MarketBeat.com Staff. From Our PartnersStocks Keep Climbing. Here's The Problem (and possible solution).Record highs and AI-fueled optimism have investors feeling confident - but every major bull market in history ...Preserve Gold | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredModerna’s 177% Surge Puts Cancer Biotech Back in FocusModerna shares surged 177% in a single trading session on August 19, adding about $45 billion in market value ...The Tomorrow Investor | SponsoredUnder $1… and Wall Street already knows about itYou've seen the crypto market… it's absolutely on fire. And the biggest catalyst could be up next. September 1...Crypto 101 Media | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | Sponsored2:59 PM Friday. I make this trade.Tim Sykes says he books gains almost every weekend using one simple move. The trade is placed around 2:59 p...Tim Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
